Literature DB >> 18266220

Incidence of Langerhans cell histiocytosis in children: a population-based study.

Helen Stålemark1, Evaldas Laurencikas, Jenny Karis, Désirée Gavhed, Bengt Fadeel, Jan-Inge Henter.   

Abstract

BACKGROUND: Langerhans cell histiocytosis is a rare disease of unknown etiology. We wanted to assess the population-based incidence of LCH in a well-defined cohort of children.
METHODS: We identified all children <15-years old treated with LCH during the 10 years period 1992-2001 at the Department of Pediatrics, Karolinska University Hospital in Stockholm, the referral center for children with LCH in Stockholm County. We also contacted the Departments of Dermatology, Orthopedics, and Neurosurgery for possible additional patients.
RESULTS: Twenty-nine children (16 males) with LCH were identified, with a median age at diagnosis of 3.8 years (2 months-13.7 years). All children but one had a definitive diagnosis of LCH. The minimum incidence of LCH is estimated to 8.9/10(6) children per year. At diagnosis, 20 children (69%) had single system (SS) and 9 (31%) multisystem (MS) manifestations. Five of the 20 children with SS eventually developed MS disease, thus 14 (48%) had MS involvement at the maximal extent of disease (4.3/10(6) children per year). Interestingly, 22 children (76%) were diagnosed during the fall (September-November, n = 12) and winter (December-February, n = 10) seasons, as compared to seven children during the spring (March-May = 1) and summer (June-August = 6) seasons (P = 0.005, Chi-square).
CONCLUSIONS: The incidence of childhood LCH in our study is higher than previously reported. In our patient cohort, LCH was more commonly diagnosed during the fall and winter season as compared to the spring and summer season. Whether this seasonal variation can be confirmed in larger studies and whether it has relevance for LCH pathophysiology remains to be elucidated. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18266220     DOI: 10.1002/pbc.21504

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  47 in total

1.  Pediatric spontaneous tension pneumothorax in Langerhans cell histiocytosis.

Authors:  Andrew L Juergens; Archana K Reddy; Matthew W Fannell; Guy H Grayson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-23

Review 2.  Pediatric lymphomas and histiocytic disorders of childhood.

Authors:  Carl E Allen; Kara M Kelly; Catherine M Bollard
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

Review 3.  Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?

Authors:  Marie-Luise Berres; Miriam Merad; Carl E Allen
Journal:  Br J Haematol       Date:  2014-11-28       Impact factor: 6.998

4.  How I treat Langerhans cell histiocytosis.

Authors:  Carl E Allen; Stephan Ladisch; Kenneth L McClain
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

Review 5.  [Histiocytosis in the dermatological context of the new classification].

Authors:  C Lang; J-T Maul; L Krähenbühl; F Dimitriou; R Dummer
Journal:  Hautarzt       Date:  2019-09       Impact factor: 0.751

Review 6.  Selected Giant Cell Rich Lesions of the Temporal Bone.

Authors:  Anthony P Martinez; Jorge Torres-Mora
Journal:  Head Neck Pathol       Date:  2018-08-01

Review 7.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

8.  The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics.

Authors:  Erin C Peckham-Gregory; Kenneth L McClain; Carl E Allen; Michael E Scheurer; Philip J Lupo
Journal:  Ann Epidemiol       Date:  2018-04-17       Impact factor: 3.797

Review 9.  Langerhans cell histiocytosis of the orbit: five clinicopathologic cases and review of the literature.

Authors:  Martina C Herwig; Ted Wojno; Qing Zhang; Hans E Grossniklaus
Journal:  Surv Ophthalmol       Date:  2012-12-13       Impact factor: 6.048

10.  Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group.

Authors:  Akira Morimoto; Chihiro Shimazaki; Satoshi Takahashi; Kouhei Yoshikawa; Ryosei Nishimura; Hisashi Wakita; Yutaka Kobayashi; Hirokazu Kanegane; Arinobu Tojo; Toshihiko Imamura; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2012-12-16       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.